Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced disease activity in patients with moderate to severe hidradenitis suppurativa, the company announced …
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) said its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in two Phase III trials, according to results from …
AstraZeneca Drug Cuts COPD Exacerbations in Phase III Trials Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced recently that its oral psoriasis treatment ICOTYDE (icotrokinra) achieved sustained skin clearance rates through 52 weeks in Phase 3 clinical …
Johnson & Johnson Reports Psoriasis Drug Results From Phase 3 Studies Read More
PHILADELPHIA, PA — Aro Biotherapeutics announced positive topline results from the Phase 1b portion of a clinical trial evaluating its investigational therapy ABX1100 for late-onset Pompe disease, showing reductions in …
Aro Biotherapeutics Reports Positive Phase 1b Data for Pompe Therapy Read More
PLYMOUTH MEETING, PA — Braeburn announced that results from a National Institutes of Health-funded clinical trial evaluating a weekly extended-release buprenorphine treatment for opioid use disorder in pregnancy were published …
NIH-Funded Study Finds Weekly Buprenorphine Effective in Pregnancy Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has partnered with NeuroRPM to integrate an FDA-cleared artificial intelligence platform into its ongoing Parkinson’s disease study to improve symptom monitoring and …
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, …
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator Read More
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said it has received written confirmation from the U.S. Food and Drug Administration supporting a path toward approval of its depression treatment …
NRx Says FDA Will Review NRX-100 Without New Trials Read More